One of the biggest challenges in precision medicine is what to do with the mountain of data generated from the sequencing of each tumor – how to parse out the relevant information and make it accessible and useful to the physicians making treatment decisions. Ultimately, such data should be available for a function called Clinical Decision Support. This function as defined by the Federal Office of the National Coordinator for Health Information Technology is “knowledge and person-speci
Latest news from The Englander Institute for Precision Medicine:
Moving with what has been cited as unprecedented speed, the National Institutes of Health (NIH) has chosen a collaboration of four New York institutions -- Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Hospital and NYC Health + Hospitals/Harlem -- to launch a landmark longitudinal research study as a part of President Barack Obama’s Precision Medicine Initiative (PMI).
Moonshot Thinking: Tumor Banking, Data Sharing, and Innovation is key
In what evolved into a cancer moonshot think tank, a special event was held at Weill Cornell Medicine on June 29, one of 270 held in tandem across the United States convened by Vice President Joe Biden, with a national summit at Howard University in Washington, DC.
Dr. Himisha Beltran represented The Englander Institute of Precision Medicine at The American Society of Clinical Oncology (#ASCO16) annual meeting over the weekend in Chicago.
At the meeting, Dr. Himisha Beltran was the chair of a session entitled “Precision Medicine in Advanced Prostate Cancer: Understanding Genomics, Androgen Receptor Splice Variants, and Imaging Biomarkers,” where she spoke about biomarker identification in prostate cancer and how clinicians can use this information to guide treatment decisions.
A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and University of Trento investigators discovered in a new study. The scientists say their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer.